Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study
- Khalid M. Mohany
- Osamah Al Rugaie
- Osama Al‑Wutayd
- Mansour Alsharidah
- Abdullah Al‑Nafeesah
Affiliations: Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt, Department of Basic Medical Sciences, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia, Department of Family and Community Medicine, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia, Department of Physiology, College of Medicine, Qassim University, Buraydah 51452, Kingdom of Saudi Arabia, Department of Pediatrics, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia
- Published online on: April 21, 2022 https://doi.org/10.3892/etm.2022.11330
Copyright: © Mohany
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The present study assessed serum miR‑15b, Annexin A1, procalcitonin, and interleukin‑6 (IL‑6) levels in children with metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) and compared them to these levels in a non‑obese healthy control group. It also tested the ability of each of these parameters to early differentiate children with MUO from those with MHO. The present study included 620 children [434 males (70%) and 186 females (30%); aged 9‑15 years] divided into the following groups: G1, healthy non‑obese controls (n=200); G2, MHO (n=246); G3, MUO (n=174). Serum miR‑15b, Annexin A1 procalcitonin, IL‑6, and other metabolic parameters levels were measured, and clinical examinations were conducted for all of the children. After testing the normality of the variable, Kruskal‑Wallis one‑way‑ANOVA, and Spearman correlation coefficients were used. The area under the receiver operating characteristic curve (AUC) was determined to test the variable's ability to differentiate MUO from MHO. miR‑15b, procalcitonin, and IL‑6 levels were significantly higher while Annexin A1 levels were significantly lower in G2 and G3 when compared to G1, and in G3 when compared to G2. These levels were positively correlated (Annexin A1 was negatively correlated) with body mass index (BMI) and waist circumference percentiles, and with serum levels of LDL‑cholesterol, glucose, HbA1c, insulin, and C‑reactive protein (CRP) and with the homeostasis model of insulin resistance (HOMA‑IR). The AUC was 0.92, 0.84, 0.82, and 0.67 for miR‑15b, Annexin A1, procalcitonin, and IL‑6, respectively. In conclusion, determination of serum miR‑15b, Annexin A1, and procalcitonin levels could differentiate children with MUO from those with MHO. This may help the early management of these cases and their accompanying complications.